CoChat

Comparative evaluation of the effects of treatment with tocilizumab and TNF-α inhibitors on serum hepcidin, anemia response and disease activity in rheumatoid arthritis patients

Open access

The DOI matches its Crossref record; the references it cites are not checked yet.

Abstract

INTRODUCTION: Anemia of inflammation (AI) is a common complication of rheumatoid arthritis (RA) and has a negative impact on RA symptoms and quality of life. Upregulation of hepcidin by inflammatory cytokines has been implicated in AI. In this study, we evaluated and compared the effects of IL-6 and TNF-α blocking therapies on anemia, disease activity, and iron-related parameters including serum hepcidin in RA patients. METHODS: Patients (n = 93) were treated with an anti-IL-6 receptor antibody (tocilizumab) or TNF-α inhibitors for 16 weeks. Major disease activity indicators and iron-related parameters including serum hepcidin-25 were monitored before and 2, 4, 8, and 16 weeks after the initiation of treatment. Effects of tocilizumab and infliximab (anti-TNF-α antibody) on cytokine-induced hepcidin expression in hepatoma cells were analyzed by quantitative real-time PCR. RESULTS: Anemia at base line was present in 66% of patients. Baseline serum hepcidin-25 levels were correlated positively with serum ferritin, C-reactive protein (CRP), vascular endothelial growth factor (VEGF) levels and Disease Activity Score 28 (DAS28). Significant improvements in anemia and disease activity, and reductions in serum hepcidin-25 levels were observed within 2 weeks in both groups, and these effects were more pronounced in the tocilizumab group than in the TNF-α inhibitors group. Serum hepcidin-25 reduction by the TNF-α inhibitor therapy was accompanied by a decrease in serum IL-6, suggesting that the effect of TNF-α on the induction of hepcidin-25 was indirect. In in vitro experiments, stimulation with the cytokine combination of IL-6+TNF-α induced weaker hepcidin expression than did with IL-6 alone, and this induction was completely suppressed by tocilizumab but not by infliximab. CONCLUSIONS: Hepcidin-mediated iron metabolism may contribute to the pathogenesis of RA-related anemia. In our cohort, tocilizumab was more effective than TNF-α inhibitors for improving anemia and normalizing iron metabolism in RA patients by inhibiting hepcidin production.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/ar4323

Cites

Statistics

Figures

Figure 1 Correlation of serum hepcidin 25 levels with serum ferritin, C-reactive protein, vascular endothelial growth factor and disease activity score in 28 joints in rheumatoid arthritis patients. Baseline values showed a significant correlation between hepcidin-25 (Hepc-25) and (A) ferritin, (B) C-reactive protein (CRP), (C) vascular endothelial growth factor (VEGF) and (D) Disease Activity Score in 28 joints (DAS28).
Figure 1 Correlation of serum hepcidin 25 levels with serum ferritin, C-reactive protein, vascular endothelial growth factor and disease activity score in 28 joints in rheumatoid arthritis patients. Baseline values showed a significant correlation between hepcidin-25 (Hepc-25) and (A) ferritin, (B) C-reactive protein (CRP), (C) vascular endothelial growth factor (VEGF) and (D) Disease Activity Score in 28 joints (DAS28).CC BY · PubMed Central
Figure 2 Correlation between serum hepcidin-25 and ferritin at observation time points after biologic drug treatment. Significant correlations were observed at (A) baseline, (B) two weeks, (C) four weeks and (D) sixteen weeks. Hepc-25, hepcidin 25.
Figure 2 Correlation between serum hepcidin-25 and ferritin at observation time points after biologic drug treatment. Significant correlations were observed at (A) baseline, (B) two weeks, (C) four weeks and (D) sixteen weeks. Hepc-25, hepcidin 25.CC BY · PubMed Central
Figure 3 Comparison of the effects of tocilizumab and tumor necrosis factor α inhibitors on hepcidin-25 and anemia-related factors in rheumatoid arthritis. Treatment effects were assessed at two, four, eight and sixteen weeks after the start of biologic drug therapy. Serum hepcidin-25 was quantified using a liquid chromatography-tandem mass spectrometry-based assay system, and other parameters were measured using standard laboratory techniques. (A) Serum levels of hepcidin-25 (Hepc-25), (B) hemoglobin (Hb), (C) serum iron (Fe) and (D) serum ferritin (Ferritin). TCZ, tocilizumab; TNFi, tumor necrosis factor α inhibitors. Values are the means and SEM. *P < 0.01 vs. baseline by paired t-test. #P < 0.01 by paired t-test comparing changes from baseline between the two groups at 16 weeks. NS, not significant.
Figure 3 Comparison of the effects of tocilizumab and tumor necrosis factor α inhibitors on hepcidin-25 and anemia-related factors in rheumatoid arthritis. Treatment effects were assessed at two, four, eight and sixteen weeks after the start of biologic drug therapy. Serum hepcidin-25 was quantified using a liquid chromatography-tandem mass spectrometry-based assay system, and other parameters were measured using standard laboratory techniques. (A) Serum levels of hepcidin-25 (Hepc-25), (B) hemoglobin (Hb), (C) serum iron (Fe) and (D) serum ferritin (Ferritin). TCZ, tocilizumab; TNFi, tumor necrosis factor α inhibitors. Values are the means and SEM. *P < 0.01 vs. baseline by paired t-test. #P < 0.01 by paired t-test comparing changes from baseline between the two groups at 16 weeks. NS, not significant.CC BY · PubMed Central
Figure 4 Comparison of effects of tocilizumab and tumor necrosis factor α inhibitors on rheumatoid arthritis disease activity during 16-week treatment. (A) C-reactive protein (CRP). (B) Vascular endothelial growth factor (VEGF). (C) Disease Activity Score in 28 joints (DAS28), tender joint count (TJC), Visual Analogue Scale (VAS) score and rheumatoid factor (RF). TCZ, tocilizumab; TNFi, tumor necrosis factor α inhibitors. Values are means and SEM. *P < 0.01, vs. baseline by paired t-test. #P < 0.01 and $P < 0.05 by paired t-test for comparison of changes from baseline between the two groups at 16 weeks.
Figure 4 Comparison of effects of tocilizumab and tumor necrosis factor α inhibitors on rheumatoid arthritis disease activity during 16-week treatment. (A) C-reactive protein (CRP). (B) Vascular endothelial growth factor (VEGF). (C) Disease Activity Score in 28 joints (DAS28), tender joint count (TJC), Visual Analogue Scale (VAS) score and rheumatoid factor (RF). TCZ, tocilizumab; TNFi, tumor necrosis factor α inhibitors. Values are means and SEM. *P < 0.01, vs. baseline by paired t-test. #P < 0.01 and $P < 0.05 by paired t-test for comparison of changes from baseline between the two groups at 16 weeks.CC BY · PubMed Central
Figure 5 Tumor necrosis factor α inhibitor treatment indirectly reduces hepcidin production in rheumatoid arthritis patients by reducing interleukin 6 levels. (A) Significant reductions in mean serum interleukin 6 (IL-6) concentrations were observed at two, four and sixteen weeks after treatment with tumor necrosis factor α (TNFα) inhibitors. (B) Effects of tocilizumab (TCZ; 25 μg/ml) and infliximab (IFX; 25 μg/ml) on hepcidin mRNA expression induced by IL-6 (10 ng/ml), TNFα (10 ng/ml), IL-1β (10 ng/ml) and their combinations in PLC/PRF/5 cells. Hepcidin mRNA was assayed by quantitative real-time PCR six hours after the stimulation. (C) IL-6 mRNA expression response to TNFα stimulation was determined in U937 cells grown in medium containing TNFα at final concentrations of 0.1, 1, 10 and 50 ng/ml. IL-6 expression increased in a dose-dependent manner. (D) Ferroportin mRNA expression response to TNFα stimulation was determined in U937 cells grown in medium containing TNFα at final concentrations of 0.1, 1, 10 and 50 ng/ml. Ferroportin expression decreased in a dose-dependent manner. The data represent means ± SD of triplicate measurements. The same experiment was repeated at least three times with consistent results, and representative data are shown. *P < 0.01 by paired t-test.
Figure 5 Tumor necrosis factor α inhibitor treatment indirectly reduces hepcidin production in rheumatoid arthritis patients by reducing interleukin 6 levels. (A) Significant reductions in mean serum interleukin 6 (IL-6) concentrations were observed at two, four and sixteen weeks after treatment with tumor necrosis factor α (TNFα) inhibitors. (B) Effects of tocilizumab (TCZ; 25 μg/ml) and infliximab (IFX; 25 μg/ml) on hepcidin mRNA expression induced by IL-6 (10 ng/ml), TNFα (10 ng/ml), IL-1β (10 ng/ml) and their combinations in PLC/PRF/5 cells. Hepcidin mRNA was assayed by quantitative real-time PCR six hours after the stimulation. (C) IL-6 mRNA expression response to TNFα stimulation was determined in U937 cells grown in medium containing TNFα at final concentrations of 0.1, 1, 10 and 50 ng/ml. IL-6 expression increased in a dose-dependent manner. (D) Ferroportin mRNA expression response to TNFα stimulation was determined in U937 cells grown in medium containing TNFα at final concentrations of 0.1, 1, 10 and 50 ng/ml. Ferroportin expression decreased in a dose-dependent manner. The data represent means ± SD of triplicate measurements. The same experiment was repeated at least three times with consistent results, and representative data are shown. *P < 0.01 by paired t-test.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists are queued

They are fetched later and appear here then.

References 33 · Cited by 143

Metadata

Authors
Song, S.-N. J., Iwahashi, M., Tomosugi, N., Uno, K., Yamana, J., Yamana, S., Isobe, T., Ito, H., Kawabata, H., & Yoshizaki, K.
Affiliations
  • The University of Osaka (JP)
  • Higashihiroshima Medical Center (JP)
  • Kanazawa Medical University (JP)
  • Louis Pasteur Center for Medical Research (JP)
  • Kyoto University (JP)
Corresponding author
Yoshizaki, Kazuyuki
Venue
Arthritis Research & Therapy
Published
2013-10-02
Volume
15
Issue
5
Pages
R141-R141
ISSN
1478-6354 (ISSN-L)
OpenAlex
W2163447382
Cited by
143
References
33
Citations by year
2026: 5 · 2025: 7 · 2024: 10 · 2023: 12 · 2022: 12 · 2021: 15 · 2020: 12 · 2019: 14 · 2018: 11 · 2017: 17 · 2016: 11 · 2015: 8 · 2014: 9
FWCI
6.69
Type
journal article
Language
en
Open access
Licence
Locations
  • Arthritis Research & Therapy (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • Ministry of Education, Culture, Sports, Science and Technology
  • Japan Society for the Promotion of Science (25460784)
Topics
  • Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
  • Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
  • Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
Keywords
rheumatoid arthritis, anemia of chronic disease, hepcidin, tocilizumab, TNF-alpha inhibitors, infliximab, IL-6 receptor inhibition, iron metabolism, disease activity, serum ferritin, C-reactive protein, vascular endothelial growth factor, hepatoma cells
MeSH terms
Infliximab, Adult, Aged, Anemia, Antibodies, Monoclonal, Arthritis, Rheumatoid, C-Reactive Protein, Female, Ferritins, Humans, Male, Middle Aged, Time Factors, Tumor Necrosis Factor-alpha, Interleukin-6, Gene Expression, Antirheumatic Agents, Reverse Transcriptase Polymerase Chain Reaction, U937 Cells, Vascular Endothelial Growth Factor A, Cell Line, Tumor, Antibodies, Monoclonal, Humanized, Hepcidins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Comparative evaluation of the effects of treatment with tocilizumab and TNF-α inhibitors on serum hepcidin, anemia response and disease activity in rheumatoid arthritis patients. https://app.cochat.ai/papers/10.1186/ar4323
The paper
Song, S.-N. J., Iwahashi, M., Tomosugi, N., Uno, K., Yamana, J., Yamana, S., Isobe, T., Ito, H., Kawabata, H., & Yoshizaki, K. (2013). Comparative evaluation of the effects of treatment with tocilizumab and TNF-α inhibitors on serum hepcidin, anemia response and disease activity in rheumatoid arthritis patients. Arthritis Research & Therapy. https://doi.org/10.1186/ar4323

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.